Publications by authors named "Gerold Meinhardt"

Claim this Profile
T
Trastuzumab Deruxtecan‒Related Interstitial Lung Disease/Pneumonitis: Computed Tomography Imaging Patterns to Guide Diagnosis and Management.
Mizuki Nishino, Masahiko Kusumoto, Alexander A Bankier, Yasuyuki Kurihara, Lin Zhang, Gerold Meinhardt

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Gerold Meinhardt

Nat Commun· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Gerold Meinhardt

N Engl J Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies.
Christoph Muysers, Alex Dmitrienko, Hermann Kulmann, Bodo Kirsch, Susanne Lippert, Gerold Meinhardt

Ther Innov Regul Sci· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Marcia S Brose, Martin Schlumbeger, Michael Jeffers, Christian Kappeler, Gerold Meinhardt

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.
Olivier Huillard, Anne Jouinot, Camille Tlemsani, Marcia S Brose, Jennifer Arrondeau, Gerold Meinhardt

Thyroid· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.
Joachim Grevel, Garrit Jentsch, Rupert Austin, Nicolaas H Prins, John Lettieri, Gerold Meinhardt

Clin Transl Sci· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Roser Pinyol, Robert Montal, Laia Bassaganyas, Daniela Sia, Tadatoshi Takayama, Gerold Meinhardt

Gut· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies.
Christoph Muysers, Alex Dmitrienko, Hermann Kulmann, Bodo Kirsch, Susanne Lippert, Gerold Meinhardt

Ther Innov Regul Sci· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Michael Teufel, Henrik Seidel, Karl Köchert, Gerold Meinhardt, Richard S Finn

Gastroenterology· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
Jordi Bruix, Ann-Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis

J Hepatol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Richard S Finn, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Gerold Meinhardt

J Hepatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
José Baselga, Claudio Zamagni, Patricia Gómez, Begoña Bermejo, Shigenori E Nagai, Gerold Meinhardt

Clin Breast Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Alexander Solms, Isabel Reinecke, Sabine Fiala-Buskies, Anne Keunecke, Henk-Jan Drenth, Gerold Meinhardt

Eur J Pharm Sci· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Jordi Bruix, Ann-Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis

J Hepatol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Shi-Ming Lin, Sheng-Nan Lu, Ping-Tsung Chen, Long-Bin Jeng, Shinn-Cherng Chen, Gerold Meinhardt

Hepatol Int· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, Gerold Meinhardt

Lancet· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
Andrew X Zhu, Yoon-Koo Kang, Olivier Rosmorduc, T R Jeffry Evans, Armando Santoro, Gerold Meinhardt

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Riccardo Lencioni, Josep M Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Gerold Meinhardt

J Hepatol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Francis Worden, Martin Fassnacht, Yuankai Shi, Tatiana Hadjieva, Françoise Bonichon, Gerold Meinhardt

Endocr Relat Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Gerold Meinhardt

Lancet Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Andrew X Zhu, Olivier Rosmorduc, T R Jeffry Evans, Paul J Ross, Armando Santoro, Gerold Meinhardt

J Clin Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Josep M Llovet, Carol E A Peña, Chetan D Lathia, Michael Shan, Gerold Meinhardt

Clin Cancer Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Masatoshi Kudo, Kazuho Imanaka, Nobuyuki Chida, Kohei Nakachi, Won-Young Tak, Gerold Meinhardt

Eur J Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
Michael I Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C Gatter, Tanja Trarbach, Gerold Meinhardt

Clin Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis